Key facts
- Active Substance
- N-Acetyl-L-Cysteine (corresponds to L-Cysteine), L-Alanine, L-Alanyl-L-Glutamine (corresponds to L-Alanine and L-Glutamine), L-Arginine, Glycine, Glycyl-L-Tyrosine (corresponds to Glycine and L-Tyrosine), L-Histidine, L-Isoleucine, L-Leucine, L-Lysine acetate (corresponds to L-Lysine), LMethionine, L-Phenylalanine, L-Proline, L-Serine, Taurine, L-Threonine, L-Tryptophan, L-Valine
- Therapeutic area
- Nutrition
- Decision number
- P/175/2009
- PIP number
- EMEA-000042-PIP01-07
- Pharmaceutical form(s)
- Solution for infusion
- Condition(s) / indication(s)
- Supplementation of amino-acids where parenteral nutrition is required.
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Fresenius Kabi Deutschland GmbH
E-mail: pr-fre@fresenius.com
Country: Germany
Phone: +49 61726080
Fax: +49 61726082294- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date